Shreelaxmi Gavas

Ms. Shreelaxmi Gavas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2021 in Discover Nano
Verified
Journal Article
Open access
PDF file
SGShreelaxmi Gavas
Shreelaxmi Gavas
SQSameer Quazi
Sameer Quazi
Tomasz M. KarpinskiTomasz M. Karpinski
Tomasz M. Karpinski
Cancer is one of the leading causes of death and morbidity with a complex pathophysiology. Traditional cancer therapies include chemotherapy, radiation therapy, targeted therapy, and immunotherapy. However, limitations such as lack of specificity, cytotoxicity, and multi-drug resistance pose a substantial challenge for favorable cancer treatment. The advent of nanotechnology has revolutionized the arena of cancer diagnosis and treatment. Nanoparticles (1–100 nm) can be used to treat cancer due to their specific advantages such as biocompatibility, reduced toxicity, more excellent stability, enhanced permeability and retention effect, and precise targeting. Nanoparticles are classified into several main categories. The nanoparticle drug delivery system is particular and utilizes tumor and tumor environment characteristics. Nanoparticles not only solve the limitations of conventional cancer treatment but also overcome multidrug resistance. Additionally, as new multidrug resistance mechanisms are unraveled and studied, nanoparticles are being investigated more vigorously. Various therapeutic implications of nanoformulations have created brand new perspectives for cancer treatment. However, most of the research is limited to in vivo and in vitro studies, and the number of approved nanodrugs has not much amplified over the years. This review discusses numerous types of nanoparticles, targeting mechanisms, and approved nanotherapeutics for oncological implications in cancer treatment. Further, we also summarize the current perspective, advantages, and challenges in clinical translation.

4 May 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
SQSameer Quazi
Sameer Quazi
MRMaliha Tabassum Rashid
Maliha Tabassum Rashid
JMJavid Ahmad Malik
Javid Ahmad Malik
SGShreelaxmi Gavas
Shreelaxmi Gavas
Multicomponent reactions (MCR) have been used to synthesize a wide range of analogs from several classes of heterocyclic compounds, with multifaceted medicinal uses. The synthesis of highly functionalized molecules in a single pot is a unique property of MCR, allowing researchers to quickly assemble libraries of compounds of biological interest and uncover novel leads as possible therapeutic agents. Isocyanide-based multicomponent reactions have proven to be extremely effective at swiftly specifying members of compound libraries, particularly in the discovery of drugs. The understanding of structure–activity correlations that drive the development of new goods and technology requires structural variety in these libraries. In today’s world, antibiotic resistance is a major ongoing problem that poses risks to public health. The implementation of isocyanide-based multicomponent reactions upholds a significant potential in this regard. By utilizing such reactions, new antimicrobial compounds can be discovered and subsequently used to fight against such concerns. This study discusses the recent developments in antimicrobial medication discovery using isocyanide-based multicomponent reactions (IMCRs). Furthermore, the article emphasizes the potential of IMCRs (Isocyanide-based multicomponent based reactions) in the near future.

12 September 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
SQSameer Quazi
Sameer Quazi
MRMaliha Tabassum Rashid
Maliha Tabassum Rashid
JMJavid Ahmad Malik
Javid Ahmad Malik
SGShreelaxmi Gavas
Shreelaxmi Gavas
The Antibiotics Editorial Office retracts the paper “The Discovery of Novel Antimicrobial Agents through the Application of Isocyanide-Based Multicomponent Reactions”

18 April 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
SQSameer Quazi
Sameer Quazi
SGShreelaxmi Gavas
Shreelaxmi Gavas
BFBahareh Farasati Far
Bahareh Farasati Far
JMJavid Ahmad Malik
Javid Ahmad Malik
MRMaliha Rashid
Maliha Rashid
Multicomponent reactions (MCR) have been used to synthesis a wide range of analogs from several classes of heterocyclic compounds, with multifaceted medicinal uses. The synthesis of highly functionalized molecules in a single pot is a unique property of MCR, allowing researchers to quickly assemble libraries of compounds of biological interest and uncover novel leads as possible therapeutic agents. Isocyanide-based multicomponent reactions have proven to be extremely effective at swiftly specifying members of compound libraries, particularly in discovery of drug . The understanding of structure-activity correlations that drive the development of new goods and technology, requires structural variety in these libraries. In current world, antibiotic resistance is a major ongoing problem which is developing a problematic scenario in public health. The implementation of isocyanide based multicomponent reactions uphold a significant potential in this regard. By utilizing such reactions, new antimicrobial compounds can be discovered and fight against such concerns. This study discusses recent developments in antimicrobial medication discovery using isocyanide-based multicomponent reactions (IMCRs). Furthermore, the article emphasizes the potential of IMCRs in the near future.